Most Fa­vored Na­tions rule for drug pric­ing: Gone, but not for­got­ten

The Cen­ters for Medicare and Med­ic­aid Ser­vices late Fri­day pro­posed to re­scind an­oth­er Trump-era drug pric­ing rule, this time for a rule that sought to low­er pre­scrip­tion drug costs by pay­ing no more for high-cost Medicare Part B drugs than the low­est price in some sim­i­lar in­ter­na­tion­al mar­kets.

The so-called Most Fa­vored Na­tion Mod­el in­ter­im fi­nal rule, which drug­mak­ers de­cried as price con­trols and Trump’s HHS pledged would save $85 bil­lion over sev­en years, nev­er got off the ground. Three dif­fer­ent law­suits, in­clud­ing one from Re­gen­eron (Part B spends more on Re­gen­eron’s Eylea than any oth­er drug), were filed to stop the rule from tak­ing ef­fect. The suits re­sult­ed in such a halt, mean­ing the rule was nev­er im­ple­ment­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.